In this reference laboratory, either reference lab or submitting hospital decide whether to test RHD molecular or not. The RHD geno here is not by HEA beadchip but by other in-house methods. For the purpose of simplicity for our transfusion services staff, we translated the RHD results in terms of potential to produce anti-D and code them in as Antigens in our LIS. If RhD negative blood is warranted, we post D* as antibody (communicated to staffs as "give D- but patient has not make anti-D), so that LIS will stop us from issuing D+ units.
For patients with weak D type1, type2 or type 3, we used the codes WKD1, WKD2, WKD3 as antigens.
For patients with RHD variants that has potential to make anti-D. we used the code WKDV as antigens. We also put in predicted RHD variant in patient's comment (for example RHD*DAR or weakD 4.2.1 etc) Also post D* in antibody profile so LIS will stop the tech from issuing D+ units.
For patients with RHD variant in heterozygote expression but also has normal D gene- we do not post anything in antigen or antibody profile. However we free text the predict allele in the patient's comment. For example, "Genomic RHD testing indicates a normal D allele with RHD* DAR1.2. (I suppose posting other terminology. like weakD 4.2.2 instead of allele name will be fine too)
Hope it is helpful